146 related articles for article (PubMed ID: 37924789)
1. Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Hwang JR; Cho YJ; Ryu JY; Choi JY; Choi JJ; Sa JK; Kim HS; Lee JW
Biomed Pharmacother; 2023 Dec; 168():115792. PubMed ID: 37924789
[TBL] [Abstract][Full Text] [Related]
2. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
3. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms.
Lewis TD; Malik M; Britten J; Parikh T; Cox J; Catherino WH
Fertil Steril; 2019 Apr; 111(4):806-815.e1. PubMed ID: 30871768
[TBL] [Abstract][Full Text] [Related]
5. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
Small B; Millard CEF; Kisanga EP; Burman A; Anam A; Flannery C; Al-Hendy A; Whirledge S
J Clin Endocrinol Metab; 2020 Mar; 105(3):716-34. PubMed ID: 31665442
[TBL] [Abstract][Full Text] [Related]
6. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study.
Del Bello B; Marcolongo P; Ciarmela P; Sorbi F; Petraglia F; Luisi S; Maellaro E
Fertil Steril; 2019 Dec; 112(6):1150-1159. PubMed ID: 31843092
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.
Noh JJ; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Choi JY; Lee JW
Clin Cancer Res; 2022 Sep; 28(17):3850-3861. PubMed ID: 35727598
[TBL] [Abstract][Full Text] [Related]
10. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
11. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation.
Courtoy GE; Donnez J; Marbaix E; Barreira M; Luyckx M; Dolmans MM
Gynecol Obstet Invest; 2018; 83(5):443-454. PubMed ID: 29227976
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
13. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Kolanska K; Varinot J; Canlorbe G; Bergeron C; Mekinian A; Capmas P; Koskas M; Daraï E; Aractingi S; Bendifallah S; Chabbert-Buffet N
Reprod Biomed Online; 2019 May; 38(5):825-834. PubMed ID: 30898512
[TBL] [Abstract][Full Text] [Related]
14. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
15. The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth.
Tinelli A; Kosmas IP; Mynbaev OA; Malvasi A; Sparic R; Vergara D
Curr Pharm Des; 2020; 26(3):310-317. PubMed ID: 31987017
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
17. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
18. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
19. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]